Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fondaparinux sodium - Sanofi aventis

Next Previous
X
Search
Drug Profile

Fondaparinux sodium - Sanofi aventis

Alternative Names: Arixtra; GSK 576428; ORG 31540; Quixidar; SR 90107; SR 90107A; Xantidar

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator sanofi-aventis
  • Developer GSK
  • Class Anticoagulants; Antithrombotics; Polysaccharides
  • Mechanism of Action Factor Xa inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute coronary syndromes; Deep vein thrombosis; Myocardial infarction; Pulmonary embolism; Thromboembolism; Unstable angina pectoris; Venous thrombosis

Most Recent Events

  • 07 Sep 2020 Mylan enters into an agreement with Aspen to acquire Fondaparinux sodium from Aspen in Europe
  • 12 Sep 2016 Aspen acquires rights for fondaparinux sodium in China, India and Pakistan from GlaxoSmithKline
  • 31 Dec 2014 Fondaparinux sodium licensed to Mylan in USA

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top